Novartis AG, a prominent player in the pharmaceutical industry, continues to receive support from UBS.

The company's sales are well-diversified across various therapeutic areas, with oncology being the largest contributor at 29.9%. Immunology follows closely at 17.2%, while cardiovascular, renal, and metabolic diseases account for 14.1%. Neuroscience represents 8.9% of sales, and contract manufacturing contributes the remaining 29.9%.

Novartis AG operates 33 production sites globally, showcasing its strong manufacturing capabilities. Geographically, the company's sales are distributed as follows: 39.5% from the USA, 33% from Europe, 20.5% from Asia-Africa-Australasia, and 7% from Canada and Latin America. This diverse portfolio positions Novartis AG favorably in the global pharmaceutical market.